Advertisement
Screener

ELI LILLY AND COMPANY (LLY) Increase (Decrease) in Other Operating Assets and Liabilities, Net

2.8 / 5 stars · 68/120 Roast Me

ELI LILLY AND COMPANY Increase (Decrease) in Other Operating Assets and Liabilities, Net

ELI LILLY AND COMPANY (LLY) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $2.33 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-08-05

  • ELI LILLY AND COMPANY increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-06-30 was $670.00M, a 70.39% decline year-over-year.
  • ELI LILLY AND COMPANY increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-03-31 was $1.66B, a 50.54% decline year-over-year.
  • ELI LILLY AND COMPANY increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was -$1.21B, a 12427.55% decline year-over-year.
  • ELI LILLY AND COMPANY increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-06-30 was $2.26B, a 61.75% increase year-over-year.
  • ELI LILLY AND COMPANY increase (decrease) in other operating assets and liabilities, net for fiscal 2009 was -$956.90M, a 203.54% decline from fiscal 2008.
  • ELI LILLY AND COMPANY increase (decrease) in other operating assets and liabilities, net for fiscal 2008 was $924.20M.
  • ELI LILLY AND COMPANY increase (decrease) in other operating assets and liabilities, net for fiscal 2007 was -$53.80M.
Period endIncrease (Decrease) in Other Operating Assets and Liabilities, Net 3 monthIncrease (Decrease) in Other Operating Assets and Liabilities, Net 3 month as first filedIncrease (Decrease) in Other Operating Assets and Liabilities, Net 6 monthIncrease (Decrease) in Other Operating Assets and Liabilities, Net 6 month as first filedIncrease (Decrease) in Other Operating Assets and Liabilities, Net 9 monthIncrease (Decrease) in Other Operating Assets and Liabilities, Net 9 month as first filedIncrease (Decrease) in Other Operating Assets and Liabilities, Net 12 month
2026-06-30$670.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$2.33B
10-Q · filed 2026-08-05
2026-03-31$1.66B
10-Q · filed 2026-04-30
2025-09-30-$1.21B
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30
$1.05B
derived: sum of 2 quarters · filed 2026-08-05
$4.42B
10-Q · filed 2025-10-30
2025-06-30$2.26B
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$5.63B
10-Q · filed 2026-08-05
$5.63B
10-Q · filed 2025-08-07
2025-03-31$3.36B
10-Q · filed 2026-04-30
$3.36B
10-Q · filed 2025-05-01
2024-09-30$9.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30
$1.41B
derived: sum of 2 quarters · filed 2025-10-30
$3.16B
10-Q · filed 2025-10-30
2024-06-30$1.40B
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$3.15B
10-Q · filed 2025-08-07
2024-03-31$1.75B
10-Q · filed 2025-05-01
2023-09-30-$793.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30
$46.90M
derived: sum of 2 quarters · filed 2024-10-30
-$117.20M
10-Q · filed 2024-10-30
2023-06-30$840.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$676.10M
10-Q · filed 2024-08-08
2023-03-31-$164.10M
10-Q · filed 2024-04-30
2022-09-30-$927.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
-$857.70M
derived: sum of 2 quarters · filed 2023-11-02
-$823.40M
10-Q · filed 2023-11-02
-$821.50M
10-Q · filed 2022-11-01
2022-06-30$69.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$104.20M
10-Q · filed 2023-08-08
$117.60M
10-Q · filed 2022-08-04
2022-03-31$34.30M
10-Q · filed 2023-04-27
$45.50M
10-Q · filed 2022-04-29
2021-09-30$666.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01
$445.30M
derived: sum of 2 quarters · filed 2022-11-01
$548.10M
10-Q · filed 2022-11-01
2021-06-30-$221.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$118.40M
10-Q · filed 2022-08-04
2021-03-31$102.80M
10-Q · filed 2022-04-29
2020-09-30-$249.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27
-$1.18B
derived: sum of 2 quarters · filed 2021-10-27
$232.20M
10-Q · filed 2021-10-27
2020-06-30-$926.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03
$481.60M
10-Q · filed 2021-08-03
2020-03-31$1.41B
10-Q · filed 2021-04-30
2019-09-30$247.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28
$1.05B
derived: sum of 2 quarters · filed 2020-10-28
$1.76B
10-Q · filed 2020-10-28
2019-06-30$802.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31
$1.52B
10-Q · filed 2020-07-31
2019-03-31$714.30M
10-Q · filed 2020-05-01
2018-09-30-$293.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-25
$368.20M
derived: sum of 2 quarters · filed 2019-10-25
$1.64B
10-Q · filed 2019-10-25
2018-06-30$662.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02
$1.93B
10-Q · filed 2019-08-02
2018-03-31$1.27B
10-Q · filed 2019-05-02
2017-09-30-$593.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06
-$469.80M
derived: sum of 2 quarters · filed 2018-11-06
$525.20M
10-Q · filed 2018-11-06
2017-06-30$123.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-25
$1.12B
10-Q · filed 2018-07-25
-$1.12B
10-Q · filed 2017-07-28
2017-03-31$995.00M
10-Q · filed 2018-04-27
-$995.00M
10-Q · filed 2017-05-01
2016-09-30$2.41B
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-27
$2.49B
derived: sum of 2 quarters · filed 2017-10-27
$1.11B
10-Q · filed 2017-10-27
-$1.22B
10-Q · filed 2016-10-28
2016-06-30$86.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28
-$1.30B
10-Q · filed 2017-07-28
-$1.40B
10-Q · filed 2016-07-28
2016-03-31-$1.38B
10-Q · filed 2017-05-01
-$1.43B
10-Q · filed 2016-04-29
2015-09-30-$75.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-28
-$49.90M
derived: sum of 2 quarters · filed 2016-10-28
-$963.60M
10-Q · filed 2016-10-28
-$660.10M
10-Q · filed 2015-10-30
2015-06-30$25.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28
-$887.80M
10-Q · filed 2016-07-28
-$686.30M
10-Q · filed 2015-07-30
2015-03-31-$913.70M
10-Q · filed 2016-04-29
2014-09-30$473.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30
$369.50M
derived: sum of 2 quarters · filed 2015-10-30
-$548.30M
10-Q · filed 2015-10-30
2014-06-30-$103.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30
-$1.02B
10-Q · filed 2015-07-30
2014-03-31-$917.80M
10-Q · filed 2015-04-30
-$941.30M
10-Q · filed 2014-04-28
2013-09-30-$226.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29
-$450.20M
derived: sum of 2 quarters · filed 2014-10-29
-$1.50B
10-Q · filed 2014-10-29
2013-06-30-$223.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-28
-$1.27B
10-Q · filed 2014-07-28
2013-03-31-$1.05B
10-Q · filed 2014-04-28
$1.05B
10-Q · filed 2013-04-26
2012-09-30$488.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30
-$970.20M
derived: sum of 2 quarters · filed 2013-10-30
-$271.50M
10-Q · filed 2013-10-30
$271.50M
10-Q · filed 2012-10-26
2012-06-30-$1.46B
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26
-$759.80M
10-Q · filed 2013-07-26
$759.80M
10-Q · filed 2012-07-27
2012-03-31$698.70M
10-Q · filed 2013-04-26
2011-09-30-$166.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-26
-$672.30M
derived: sum of 2 quarters · filed 2012-10-26
-$76.70M
10-Q · filed 2012-10-26
$76.70M
10-Q · filed 2011-10-28
2011-06-30-$506.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-27
$89.40M
10-Q · filed 2012-07-27
-$89.40M
10-Q · filed 2011-07-29
2011-03-31$595.60M
10-Q · filed 2012-04-30
-$595.60M
10-Q · filed 2011-04-29
2010-09-30-$116.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28
-$5.20M
derived: sum of 2 quarters · filed 2011-10-28
-$820.30M
10-Q · filed 2011-10-28
-$9.20M
derived: sum of 4 quarters · filed 2011-10-28
2010-06-30$111.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-29
-$703.50M
10-Q · filed 2011-07-29
$107.60M
derived: sum of 3 quarters · filed 2011-07-29
-$465.50M
derived: sum of 4 quarters · filed 2011-07-29
2010-03-31-$815.10M
10-Q · filed 2011-04-29
-$4.00M
derived: sum of 2 quarters · filed 2011-04-29
-$577.10M
derived: sum of 3 quarters · filed 2011-04-29
-$1.10B
derived: sum of 4 quarters · filed 2011-04-29
2009-12-31$811.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2010-02-22
$238.00M
derived: sum of 2 quarters · filed 2010-10-29
-$284.90M
derived: sum of 3 quarters · filed 2010-10-29
-$956.90M
10-K · filed 2010-02-22
2009-09-30-$573.10M
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2010-10-29
-$1.10B
derived: sum of 2 quarters · filed 2010-10-29
-$1.77B
10-Q · filed 2010-10-29
-$987.80M
derived: sum of 4 quarters · filed 2010-10-29
2009-06-30-$522.90M
derived: 10-Q/A 6 month − 10-Q 3 month · filed 2010-08-02
-$1.19B
10-Q/A · filed 2010-08-02
-$414.70M
derived: sum of 3 quarters · filed 2010-08-02
-$219.40M
derived: sum of 4 quarters · filed 2010-08-02
2009-03-31-$672.00M
10-Q · filed 2010-07-30
$108.20M
derived: sum of 2 quarters · filed 2010-07-30
$303.50M
derived: sum of 3 quarters · filed 2010-07-30
2008-12-31$780.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2010-02-22
$975.50M
derived: sum of 2 quarters · filed 2010-02-22
$924.20M
10-K · filed 2010-02-22
2008-09-30$195.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-30
$144.00M
10-Q · filed 2009-10-30
2008-06-30-$51.30M
10-Q · filed 2009-07-31
2007-12-31-$53.80M
10-K · filed 2010-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
Akari Therapeutics Plc (AKTX)$1,527.991B-47,921.42
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
AbbVie Inc. (ABBV)United States$468.180B70.37
Merck & Co., Inc. (MRK)United States$365.215B99.96
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94